Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

News

Roger Federer Announces Retirement From Tennis

-Wall Street Journal-Wall Street Journal

byBenzinga Newsdesk

September 15, 2022

1 minute read

-Wall Street Journal

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker And Preclinical Data Supporting A Phase 2 Clinical Trial With CT1812 In Geographic Atrophy Secondary To Dry AMD

By Benzinga Newsdesk

December 1, 8:32 AM

Cognition Therapeutics, Inc., (NASDAQ:CGTX), (the "Company" or "Cognition") today announced that the scientific rationale, supporting proof-of-concept data and design of the planned Phase 2 trial of

CGTX

Cato Rewards Shareholders With Dividend Hike

By Shivani Kumaresan

August 27, 11:39 AM

Cato Corp (NYSE:CATO) board of directors has approved a 55% increase in the quarterly dividend to $0.17 per share. The dividend…

CATO

Is POET Technologies Inc. IPO a Good Investment?

By Benzinga Contributor

March 11, 11:04 AM

OTCQX:POETD

POETD

BOK Financial Q3 EPS $2.32 Beats $1.99 Estimate, Sales $506.02M Beat $458.20M Estimate

By Benzinga Newsdesk

October 26, 7:59 AM

BOK Financial (NASDAQ:BOKF) reported quarterly earnings of $2.32 per share which beat the analyst consensus estimate of $1.99 by 16.58 percent. This is a 15.33 percent decrease over earnings of $2.74 per share from the

BOKF

Roger Federer Announces Retirement From Tennis

Related Posts

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker And Preclinical Data Supporting A Phase 2 Clinical Trial With CT1812 In Geographic Atrophy Secondary To Dry AMD

Cato Rewards Shareholders With Dividend Hike

Is POET Technologies Inc. IPO a Good Investment?

BOK Financial Q3 EPS $2.32 Beats $1.99 Estimate, Sales $506.02M Beat $458.20M Estimate